Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 8/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915918 | 0.86 | LPAR1 (0.52) | LPAR1LPAR3MAPTOPRM1 | |
| SCHEMBL9915929 | 0.84 | LPAR1 (0.45) | LPAR1LPAR3GSK3BMAPTSLC22A12 | |
| SCHEMBL9899954 | 0.84 | LPAR1 (0.67) | LPAR1LPAR3 | |
| SCHEMBL15261910 | 0.84 | LPAR1 (0.45) | LPAR1LPAR3GSK3BMAPTSLC22A12 | |
| SCHEMBL15261662 | 0.84 | LPAR1 (0.67) | LPAR1LPAR3 | |
| SCHEMBL9915902 | 0.80 | RORC (0.49) | LPAR1LPAR3KDM4C | |
| SCHEMBL9900134 | 0.78 | LPAR1 (0.54) | LPAR1LPAR3 | |
| SCHEMBL14711583 | 0.78 | LPAR1 (0.65) | LPAR1LPAR3MAPTSLC22A12 | |
| SCHEMBL12989462 | 0.76 | LPAR1 (0.87) | LPAR1LPAR3 | |
| SCHEMBL9899768 | 0.76 | RPS6KA3 (0.56) | GSK3BMAPTRPS6KA3SLC22A12GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | LPAR2, LPAR1, LPAR4 | LPAR1 2/4885LPAR3 6/4885GSK3B 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.